Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc. > On the Radar In Japan :-}
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(750)
•••
Comment by DeathXray33on Mar 25, 2024 10:11am
287 Views
Post# 35950551

RE:RE:On the Radar In Japan :-}

RE:RE:On the Radar In Japan :-}
wildbird1 wrote: ''This groundbreaking technology innovates NMIBC treatment and marks a transformative shift in medical technology paradigms''.
You have to love this quote!

We talk a lot about TLT getting BTD approval and one large pharma deal.

But what would happen to the SP, if Dr.Lbiati was to sign more than one large pharma deal.
-One in North-America.
-A few months later one in Europe.
-A few months later one in Asia.

Nothing wrong with dreaming( for now let's start with just one).

Oden6570 wrote:
 




@ > 1.316 million now & going up every week. Leaders not followers...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities